Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Preclinical development of a miR-132 inhibitor for heart failure treatment.

Foinquinos A, Batkai S, Genschel C, Viereck J, Rump S, Gyöngyösi M, Traxler D, Riesenhuber M, Spannbauer A, Lukovic D, Weber N, Zlabinger K, Hašimbegović E, Winkler J, Fiedler J, Dangwal S, Fischer M, de la Roche J, Wojciechowski D, Kraft T, Garamvölgyi R, Neitzel S, Chatterjee S, Yin X, Bär C, Mayr M, Xiao K, Thum T.

Nat Commun. 2020 Jan 31;11(1):633. doi: 10.1038/s41467-020-14349-2.

2.

MiR-21, MiR-29a, GATA4, and MEF2c Expression Changes in Endothelin-1 and Angiotensin II Cardiac Hypertrophy Stimulated Isl-1+Sca-1+c-kit+ Porcine Cardiac Progenitor Cells In Vitro.

Zlabinger K, Spannbauer A, Traxler D, Gugerell A, Lukovic D, Winkler J, Mester-Tonczar J, Podesser B, Gyöngyösi M.

Cells. 2019 Nov 9;8(11). pii: E1416. doi: 10.3390/cells8111416.

3.

Reduced histologic neo in-stent restenosis after use of a paclitaxel-coated cutting balloon in porcine coronary arteries.

Traxler D, Hemetsberger R, Spannbauer A, Zlabinger K, Gugerell A, Lukovic D, Mandic L, Pavo N, Winkler J, Gyöngyösi M.

Histol Histopathol. 2019 Oct 24:18177. doi: 10.14670/HH-18-177. [Epub ahead of print]

PMID:
31646547
4.

Large Animal Models of Heart Failure With Reduced Ejection Fraction (HFrEF).

Spannbauer A, Traxler D, Zlabinger K, Gugerell A, Winkler J, Mester-Tonczar J, Lukovic D, Müller C, Riesenhuber M, Pavo N, Gyöngyösi M.

Front Cardiovasc Med. 2019 Aug 14;6:117. doi: 10.3389/fcvm.2019.00117. eCollection 2019. Review.

5.

Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance.

Gyöngyösi M, Lukovic D, Zlabinger K, Spannbauer A, Gugerell A, Pavo N, Traxler D, Pils D, Maurer G, Jakab A, Riesenhuber M, Pircher A, Winkler J, Bergler-Klein J.

Cardiovasc Res. 2019 Jul 25. pii: cvz192. doi: 10.1093/cvr/cvz192. [Epub ahead of print]

PMID:
31346605
6.

Effect of Ischemic Preconditioning and Postconditioning on Exosome-Rich Fraction microRNA Levels, in Relation with Electrophysiological Parameters and Ventricular Arrhythmia in Experimental Closed-Chest Reperfused Myocardial Infarction.

Spannbauer A, Traxler D, Lukovic D, Zlabinger K, Winkler J, Gugerell A, Ferdinandy P, Hausenloy DJ, Pavo N, Emmert MY, Hoerstrup SP, Jakab A, Gyöngyösi M, Riesenhuber M.

Int J Mol Sci. 2019 Apr 30;20(9). pii: E2140. doi: 10.3390/ijms20092140.

7.

Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129.

Gomes CPC, Ágg B, Andova A, Arslan S, Baker A, Barteková M, Beis D, Betsou F, Wettinger SB, Bugarski B, Condorelli G, Silva GJJD, Danilin S, de Gonzalo-Calvo D, Buil A, Carmo-Fonseca M, Enguita FJ, Felekkis K, Ferdinandy P, Gyöngyösi M, Hackl M, Karaduzovic-Hadziabdic K, Hellemans J, Heymans S, Hlavackova M, Hoydal MA, Jankovic A, Jusic A, Kardassis D, Kerkelä R, Kuster GM, Lakkisto P, Leszek P, Lustrek M, Maegdefessel L, Martelli F, Novella S, O'Brien T, Papaneophytou C, Pedrazzini T, Pinet F, Popescu O, Potočnjak I, Robinson E, Sasson S, Scholz M, Simionescu M, Stoll M, Varga ZV, Vinciguerra M, Xuereb A, Yilmaz MB, Emanueli C, Devaux Y, on behalf of the EU-CardioRNA COST Action (CA17129).

Noncoding RNA. 2019 Mar 29;5(2). pii: E31. doi: 10.3390/ncrna5020031.

8.

Increased granulocyte membrane neprilysin (CD10) expression is associated with better prognosis in heart failure.

Pavo N, Gugerell A, Goliasch G, Bartko PE, Arfsten H, Novak JF, Gyöngyösi M, Hülsmann M.

Eur J Heart Fail. 2019 Apr;21(4):537-539. doi: 10.1002/ejhf.1441. Epub 2019 Mar 3. No abstract available.

9.

Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE).

Paitazoglou C, Bergmann MW, Vrtovec B, Chamuleau SAJ, van Klarenbosch B, Wojakowski W, Michalewska-Włudarczyk A, Gyöngyösi M, Ekblond A, Haack-Sørensen M, Jaquet K, Vrangbaek K, Kastrup J; SCIENCE Investigators.

Eur J Heart Fail. 2019 Aug;21(8):1032-1041. doi: 10.1002/ejhf.1412. Epub 2019 Feb 20.

10.

C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-Regulatory Function.

Wang Y, Dembowsky K, Chevalier E, Stüve P, Korf-Klingebiel M, Lochner M, Napp LC, Frank H, Brinkmann E, Kanwischer A, Bauersachs J, Gyöngyösi M, Sparwasser T, Wollert KC.

Circulation. 2019 Apr 9;139(15):1798-1812. doi: 10.1161/CIRCULATIONAHA.118.036053.

11.

Transcriptional Alterations by Ischaemic Postconditioning in a Pig Infarction Model: Impact on Microvascular Protection.

Lukovic D, Gugerell A, Zlabinger K, Winkler J, Pavo N, Baranyai T, Giricz Z, Varga ZV, Riesenhuber M, Spannbauer A, Traxler D, Jakab A, Garamvölgyi R, Petnehazy Ö, Pils D, Tóth L, Schulz R, Ferdinandy P, Gyöngyösi M.

Int J Mol Sci. 2019 Jan 15;20(2). pii: E344. doi: 10.3390/ijms20020344.

12.

Chronic rupture of the left ventricular wall with a giant pseudoaneurysm.

Riesenhuber M, Schneider M, Maier A, Rohla M, Gyöngyösi M.

Eur Heart J Cardiovasc Imaging. 2019 Feb 1;20(2):242. doi: 10.1093/ehjci/jey186. No abstract available.

13.

Transcatheter aortic valve replacement (TAVR) leads to an increase in the subendocardial viability ratio assessed by pulse wave analysis.

Müller C, Goliasch G, Schachinger S, Kastl S, Neunteufl T, Delle-Karth G, Kastner J, Gyöngyösi M, Lang I, Gottsauner-Wolf M, Pavo N.

PLoS One. 2018 Nov 21;13(11):e0207537. doi: 10.1371/journal.pone.0207537. eCollection 2018.

14.

9-year clinical follow-up of patients with ST-segment elevation myocardial infarction with Genous or TAXUS Liberté stents.

Giurgea GA, Heuberger A, Babayev J, Winkler S, Schlager O, Lang IM, Gyöngyösi M.

PLoS One. 2018 Aug 6;13(8):e0201416. doi: 10.1371/journal.pone.0201416. eCollection 2018.

15.

Meta-Analysis of Cell Therapy Studies in Heart Failure and Acute Myocardial Infarction.

Gyöngyösi M, Haller PM, Blake DJ, Martin Rendon E.

Circ Res. 2018 Jul 6;123(2):301-308. doi: 10.1161/CIRCRESAHA.117.311302.

PMID:
29976694
16.

Remote ischaemic conditioning for myocardial infarction or elective PCI: systematic review and meta-analyses of randomised trials.

Haller PM, Vargas KG, Haller MC, Piackova E, Wojta J, Gyöngyösi M, Gersh BJ, Kiss A, Podesser BK, Huber K.

Eur Heart J Acute Cardiovasc Care. 2018 Jun 1:2048872618784150. doi: 10.1177/2048872618784150. [Epub ahead of print]

PMID:
29911392
17.

Matrix Metalloproteinase-2 Impairs Homing of Intracoronary Delivered Mesenchymal Stem Cells in a Porcine Reperfused Myocardial Infarction: Comparison With Intramyocardial Cell Delivery.

Zlabinger K, Lukovic D, Hemetsberger R, Gugerell A, Winkler J, Mandic L, Traxler D, Spannbauer A, Wolbank S, Zanoni G, Kaun C, Posa A, Gyenes A, Petrasi Z, Petnehazy Ö, Repa I, Hofer-Warbinek R, de Martin R, Gruber F, Charwat S, Huber K, Pavo N, Pavo IJ, Nyolczas N, Kraitchman DL, Gyöngyösi M.

Front Bioeng Biotechnol. 2018 Apr 4;6:35. doi: 10.3389/fbioe.2018.00035. eCollection 2018.

18.

Preclinical Studies of Stem Cell Therapy for Heart Disease.

Tompkins BA, Balkan W, Winkler J, Gyöngyösi M, Goliasch G, Fernández-Avilés F, Hare JM.

Circ Res. 2018 Mar 30;122(7):1006-1020. doi: 10.1161/CIRCRESAHA.117.312486. Review.

PMID:
29599277
19.

Low- and High-renin Heart Failure Phenotypes with Clinical Implications.

Pavo N, Goliasch G, Wurm R, Novak J, Strunk G, Gyöngyösi M, Poglitsch M, Säemann MD, Hülsmann M.

Clin Chem. 2018 Mar;64(3):597-608. doi: 10.1373/clinchem.2017.278705. Epub 2017 Nov 14.

PMID:
29138270
20.

Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis.

Ferreira JP, Machu JL, Girerd N, Jaisser F, Thum T, Butler J, González A, Diez J, Heymans S, McDonald K, Gyöngyösi M, Firat H, Rossignol P, Pizard A, Zannad F.

ESC Heart Fail. 2018 Feb;5(1):139-148. doi: 10.1002/ehf2.12218. Epub 2017 Oct 7. Review.

21.

Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension.

Gyöngyösi M, Pavo N, Lukovic D, Zlabinger K, Spannbauer A, Traxler D, Goliasch G, Mandic L, Bergler-Klein J, Gugerell A, Jakab A, Szankai Z, Toth L, Garamvölgyi R, Maurer G, Jaisser F, Zannad F, Thum T, Bátkai S, Winkler J.

J Transl Med. 2017 Oct 6;15(1):202. doi: 10.1186/s12967-017-1299-0.

22.

Intrinsic remote conditioning of the myocardium as a comprehensive cardiac response to ischemia and reperfusion.

Pavo N, Lukovic D, Zlabinger K, Lorant D, Goliasch G, Winkler J, Pils D, Auer K, Ankersmit HJ, Giricz Z, Sárközy M, Jakab A, Garamvölgyi R, Emmert MY, Hoerstrup SP, Hausenloy DJ, Ferdinandy P, Maurer G, Gyöngyösi M.

Oncotarget. 2017 Jun 12;8(40):67227-67240. doi: 10.18632/oncotarget.18438. eCollection 2017 Sep 15.

23.

Analysis of region specific gene expression patterns in the heart and systemic responses after experimental myocardial ischemia.

Zimmermann M, Beer L, Ullrich R, Lukovic D, Simader E, Traxler D, Wagner T, Nemec L, Altenburger L, Zuckermann A, Gyöngyösi M, Ankersmit HJ, Mildner M.

Oncotarget. 2017 May 17;8(37):60809-60825. doi: 10.18632/oncotarget.17955. eCollection 2017 Sep 22.

24.

Cardioprotective Effect of Selective Estrogen Receptor Modulator Raloxifene Are Mediated by Heme Oxygenase in Estrogen-Deficient Rat.

Posa A, Szabó R, Kupai K, Berkó AM, Veszelka M, Szűcs G, Börzsei D, Gyöngyösi M, Pávó I, Deim Z, Szilvássy Z, Juhász B, Varga C.

Oxid Med Cell Longev. 2017;2017:2176749. doi: 10.1155/2017/2176749. Epub 2017 Jul 9.

25.

Mesenchymal stromal cell therapy as treatment for ischemic heart failure: the MSC-HF study.

Martin-Rendon E, Gyöngyösi M.

Cardiovasc Diagn Ther. 2017 Jun;7(Suppl 2):S69-S72. doi: 10.21037/cdt.2016.11.13. No abstract available.

26.

First-in-Man Trial of SiO2 Inert-Coated Bare Metal Stent System in Native Coronary Stenosis - The AXETIS FIM Trial.

Asano T, Suwannasom P, Katagiri Y, Miyazaki Y, Sotomi Y, Kraak RP, Wykrzykowska J, Rensing BJ, Piek JJ, Gyöngyösi M, Serruys PW, Onuma Y.

Circ J. 2018 Jan 25;82(2):477-485. doi: 10.1253/circj.CJ-17-0337. Epub 2017 Jul 14.

27.

In vivo MRI and ex vivo histological assessment of the cardioprotection induced by ischemic preconditioning, postconditioning and remote conditioning in a closed-chest porcine model of reperfused acute myocardial infarction: importance of microvasculature.

Baranyai T, Giricz Z, Varga ZV, Koncsos G, Lukovic D, Makkos A, Sárközy M, Pávó N, Jakab A, Czimbalmos C, Vágó H, Ruzsa Z, Tóth L, Garamvölgyi R, Merkely B, Schulz R, Gyöngyösi M, Ferdinandy P.

J Transl Med. 2017 Apr 1;15(1):67. doi: 10.1186/s12967-017-1166-z.

28.

Inhibition of CD34+ cell migration by matrix metalloproteinase-2 during acute myocardial ischemia, counteracted by ischemic preconditioning.

Lukovic D, Zlabinger K, Gugerell A, Spannbauer A, Pavo N, Mandic L, Weidenauer DT, Kastl S, Kaun C, Posa A, Sabdyusheva Litschauer I, Winkler J, Gyöngyösi M.

Version 3. F1000Res. 2016 Nov 22 [revised 2017 Jan 1];5:2739. doi: 10.12688/f1000research.9957.3. eCollection 2016.

29.

Sequential activation of different pathway networks in ischemia-affected and non-affected myocardium, inducing intrinsic remote conditioning to prevent left ventricular remodeling.

Pavo N, Lukovic D, Zlabinger K, Zimba A, Lorant D, Goliasch G, Winkler J, Pils D, Auer K, Jan Ankersmit H, Giricz Z, Baranyai T, Sárközy M, Jakab A, Garamvölgyi R, Emmert MY, Hoerstrup SP, Hausenloy DJ, Ferdinandy P, Maurer G, Gyöngyösi M.

Sci Rep. 2017 Mar 7;7:43958. doi: 10.1038/srep43958.

30.

Myocardial fibrosis: biomedical research from bench to bedside.

Gyöngyösi M, Winkler J, Ramos I, Do QT, Firat H, McDonald K, González A, Thum T, Díez J, Jaisser F, Pizard A, Zannad F.

Eur J Heart Fail. 2017 Feb;19(2):177-191. doi: 10.1002/ejhf.696. Review.

31.

Safety and efficacy of cardiopoietic stem cells in the treatment of post-infarction left-ventricular dysfunction - From cardioprotection to functional repair in a translational pig infarction model.

Emmert MY, Wolint P, Jakab A, Sheehy SP, Pasqualini FS, Nguyen TDL, Hilbe M, Seifert B, Weber B, Brokopp CE, Macejovska D, Caliskan E, von Eckardstein A, Schwartlander R, Vogel V, Falk V, Parker KK, Gyöngyösi M, Hoerstrup SP.

Biomaterials. 2017 Apr;122:48-62. doi: 10.1016/j.biomaterials.2016.11.029. Epub 2016 Nov 23.

PMID:
28107664
32.

Renin-Angiotensin System Fingerprints of Heart Failure With Reduced Ejection Fraction.

Pavo N, Wurm R, Goliasch G, Novak JF, Strunk G, Gyöngyösi M, Poglitsch M, Säemann MD, Hülsmann M.

J Am Coll Cardiol. 2016 Dec 27;68(25):2912-2914. doi: 10.1016/j.jacc.2016.10.017. No abstract available.

33.

Is increased homocysteine level a false trail or an accomplice to saphenous venous graft degeneration?

Gyöngyösi M.

Anatol J Cardiol. 2016 Nov;16(11):874. doi: 10.14744/AnatolJCardiol.2016.21433. No abstract available.

34.

Peripheral blood mononuclear cell secretome for tissue repair.

Beer L, Mildner M, Gyöngyösi M, Ankersmit HJ.

Apoptosis. 2016 Dec;21(12):1336-1353. Review.

35.

Long-Term Outcome of Combined (Percutaneous Intramyocardial and Intracoronary) Application of Autologous Bone Marrow Mononuclear Cells Post Myocardial Infarction: The 5-Year MYSTAR Study.

Gyöngyösi M, Giurgea GA, Syeda B, Charwat S, Marzluf B, Mascherbauer J, Jakab A, Zimba A, Sárközy M, Pavo N, Sochor H, Graf S, Lang I, Maurer G, Bergler-Klein J; MYSTAR investigators.

PLoS One. 2016 Oct 20;11(10):e0164908. doi: 10.1371/journal.pone.0164908. eCollection 2016.

36.

Molecular Imaging of Angiogenesis in Cardiac Regeneration.

Mandic L, Traxler D, Gugerell A, Zlabinger K, Lukovic D, Pavo N, Goliasch G, Spannbauer A, Winkler J, Gyöngyösi M.

Curr Cardiovasc Imaging Rep. 2016;9(10):27. Epub 2016 Sep 10. Review.

37.

Coating of intravascular balloon with paclitaxel prevents constrictive remodeling of the dilated porcine femoral artery due to inhibition of intimal and media fibrosis.

Pavo N, Samaha E, Sabdyusheva I, von Strandmann RP, Stahnke S, Plass CA, Zlabinger K, Lukovic D, Jambrik Z, Pavo IJ, Bergler-Klein J, Gray WA, Maurer G, Gyöngyösi M.

J Mater Sci Mater Med. 2016 Aug;27(8):131. doi: 10.1007/s10856-016-5737-y. Epub 2016 Jul 7.

38.

Meta-Analyses of Human Cell-Based Cardiac Regeneration Therapies: Controversies in Meta-Analyses Results on Cardiac Cell-Based Regenerative Studies.

Gyöngyösi M, Wojakowski W, Navarese EP, Moye LÀ; ACCRUE Investigators.

Circ Res. 2016 Apr 15;118(8):1254-63. doi: 10.1161/CIRCRESAHA.115.307347.

39.

Three dimensional fusion of electromechanical mapping and magnetic resonance imaging for real-time navigation of intramyocardial cell injections in a porcine model of chronic myocardial infarction.

van Slochteren FJ, van Es R, Gyöngyösi M, van der Spoel TI, Koudstaal S, Leiner T, Doevendans PA, Chamuleau SA.

Int J Cardiovasc Imaging. 2016 May;32(5):833-43. doi: 10.1007/s10554-016-0852-x. Epub 2016 Feb 16.

40.

Out-of-Hospital Cardiac Arrest in Acute Myocardial Infarction and STEMI Networks.

Benedek T, Gyöngyösi M.

J Crit Care Med (Targu Mures). 2016 Feb 9;2(1):3-5. doi: 10.1515/jccm-2016-0007. eCollection 2016 Jan. No abstract available.

41.

Analysis of the Secretome of Apoptotic Peripheral Blood Mononuclear Cells: Impact of Released Proteins and Exosomes for Tissue Regeneration.

Beer L, Zimmermann M, Mitterbauer A, Ellinger A, Gruber F, Narzt MS, Zellner M, Gyöngyösi M, Madlener S, Simader E, Gabriel C, Mildner M, Ankersmit HJ.

Sci Rep. 2015 Nov 16;5:16662. doi: 10.1038/srep16662.

42.

Human recombinant activated protein C-coated stent for the prevention of restenosis in porcine coronary arteries.

Lukovic D, Nyolczas N, Hemetsberger R, Pavo IJ, Pósa A, Behnisch B, Horak G, Zlabinger K, Gyöngyösi M.

J Mater Sci Mater Med. 2015 Oct;26(10):241. doi: 10.1007/s10856-015-5580-6. Epub 2015 Sep 28.

43.

Endogenous Estrogen-Mediated Heme Oxygenase Regulation in Experimental Menopause.

Pósa A, Szabó R, Csonka A, Veszelka M, Berkó AM, Baráth Z, Ménesi R, Pávó I, Gyöngyösi M, László F, Kupai K, Varga C.

Oxid Med Cell Longev. 2015;2015:429713. doi: 10.1155/2015/429713. Epub 2015 May 6.

44.

Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification.

Varga ZV, Giricz Z, Bencsik P, Madonna R, Gyongyosi M, Schulz R, Mayr M, Thum T, Puskas LG, Ferdinandy P.

Curr Drug Targets. 2015;16(8):904-11. Review.

PMID:
25915487
45.

Dual-source cardiac computed tomography angiography (CCTA) in the follow-up of cardiac transplant: comparison of image quality and radiation dose using three different imaging protocols.

Beitzke D, Berger-Kulemann V, Schöpf V, Unterhumer S, Spitzer E, Feuchtner GM, Gyöngyösi M, Uyanik-Uenal K, Zuckermann A, Loewe C, Wolf F.

Eur Radiol. 2015 Aug;25(8):2310-7. doi: 10.1007/s00330-015-3650-2. Epub 2015 Apr 26.

PMID:
25913571
46.

Cardioprotective effects of voluntary exercise in a rat model: role of matrix metalloproteinase-2.

Pósa A, Szabó R, Kupai K, Baráth Z, Szalai Z, Csonka A, Veszelka M, Gyöngyösi M, Radák Z, Ménesi R, Pávó I, Berkó AM, Varga C.

Oxid Med Cell Longev. 2015;2015:876805. doi: 10.1155/2015/876805. Epub 2015 Mar 22.

47.

Valvuloplasty with a paclitaxel-eluting balloon prevents restenosis in an experimental animal model of aortic stenosis.

Spargias K, Gyöngyösi M, Hemetsberger R, Posa A, Pavo N, Pavo IJ, Huber K, Petrasi Z, Petnehazy O, von Strandmann RP, Park J, Glogar D, Maurer G, Rajamannan NM.

J Heart Valve Dis. 2014 Jul;23(4):484-91.

PMID:
25803975
48.

The secretome of apoptotic human peripheral blood mononuclear cells attenuates secondary damage following spinal cord injury in rats.

Haider T, Höftberger R, Rüger B, Mildner M, Blumer R, Mitterbauer A, Buchacher T, Sherif C, Altmann P, Redl H, Gabriel C, Gyöngyösi M, Fischer MB, Lubec G, Ankersmit HJ.

Exp Neurol. 2015 May;267:230-42. doi: 10.1016/j.expneurol.2015.03.013. Epub 2015 Mar 19.

49.

Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data.

Gyöngyösi M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, Marban E, Assmus B, Henry TD, Traverse JH, Moyé LA, Sürder D, Corti R, Huikuri H, Miettinen J, Wöhrle J, Obradovic S, Roncalli J, Malliaras K, Pokushalov E, Romanov A, Kastrup J, Bergmann MW, Atsma DE, Diederichsen A, Edes I, Benedek I, Benedek T, Pejkov H, Nyolczas N, Pavo N, Bergler-Klein J, Pavo IJ, Sylven C, Berti S, Navarese EP, Maurer G; ACCRUE Investigators.

Circ Res. 2015 Apr 10;116(8):1346-60. doi: 10.1161/CIRCRESAHA.116.304346. Epub 2015 Feb 19.

50.

Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation).

De Luca G, Van't Hof AW, Gibson CM, Cutlip D, Zeymer U, Noc M, Maioli M, Zorman S, Gabriel HM, Emre A, Rakowski T, Gyongyosi M, Huber K, Bellandi F, Dudek D; EGYPT cooperation.

Am J Cardiol. 2015 Mar 15;115(6):711-5. doi: 10.1016/j.amjcard.2014.12.030. Epub 2015 Jan 6.

PMID:
25655867

Supplemental Content

Loading ...
Support Center